TR200000913T2 - Tıbbi maddeler - Google Patents

Tıbbi maddeler

Info

Publication number
TR200000913T2
TR200000913T2 TR2000/00913T TR200000913T TR200000913T2 TR 200000913 T2 TR200000913 T2 TR 200000913T2 TR 2000/00913 T TR2000/00913 T TR 2000/00913T TR 200000913 T TR200000913 T TR 200000913T TR 200000913 T2 TR200000913 T2 TR 200000913T2
Authority
TR
Turkey
Prior art keywords
medical substances
substances
medical
treatment
relates
Prior art date
Application number
TR2000/00913T
Other languages
English (en)
Inventor
Wayne Mangel Allen
Ruth Northctt Allison
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000913(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200000913T2 publication Critical patent/TR200000913T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bu bulus kabiz olmayan disi IBS hastalarinin tedavisinde 5-HT3 resepyörü antagonistlerinin kullanimina iliskindir.
TR2000/00913T 1997-10-07 1998-10-05 Tıbbi maddeler TR200000913T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments

Publications (1)

Publication Number Publication Date
TR200000913T2 true TR200000913T2 (tr) 2001-01-22

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00913T TR200000913T2 (tr) 1997-10-07 1998-10-05 Tıbbi maddeler

Country Status (36)

Country Link
US (3) US6284770B1 (tr)
EP (1) EP1021174A2 (tr)
JP (1) JP2001518495A (tr)
KR (1) KR20010015707A (tr)
CN (1) CN1281357A (tr)
AP (1) AP2000001785A0 (tr)
AR (1) AR017296A1 (tr)
AU (1) AU750818B2 (tr)
BR (1) BR9812886A (tr)
CA (1) CA2305751A1 (tr)
CO (1) CO5011096A1 (tr)
DZ (1) DZ2618A1 (tr)
EA (1) EA003184B1 (tr)
EE (1) EE200000214A (tr)
GB (1) GB9721139D0 (tr)
GT (1) GT199800157A (tr)
HN (1) HN1998000155A (tr)
HR (1) HRP20000198A2 (tr)
HU (1) HUP0003750A3 (tr)
ID (1) ID23874A (tr)
IL (1) IL135398A0 (tr)
IS (1) IS5425A (tr)
MA (1) MA26549A1 (tr)
NO (1) NO20001776L (tr)
NZ (1) NZ503698A (tr)
PA (1) PA8461101A1 (tr)
PE (1) PE120299A1 (tr)
PL (1) PL340337A1 (tr)
SK (1) SK4862000A3 (tr)
SV (1) SV1998000122A (tr)
TN (1) TNSN98179A1 (tr)
TR (1) TR200000913T2 (tr)
UY (1) UY25200A1 (tr)
WO (1) WO1999017755A2 (tr)
YU (1) YU20600A (tr)
ZA (1) ZA989061B (tr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
JP2004508056A (ja) * 2000-09-06 2004-03-18 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
DE60143671D1 (de) * 2001-06-07 2011-01-27 Sang Christine Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
AU2003210610B2 (en) * 2002-01-18 2007-11-29 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
CN1668307A (zh) * 2002-07-10 2005-09-14 阿瑞科诺沃治疗有限公司 治疗功能性肠紊乱的4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并[2,3－d]嘧啶
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
EP1541172A1 (en) * 2002-08-09 2005-06-15 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
KR20050111318A (ko) * 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
EP1594493A2 (en) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
PL380448A1 (pl) * 2004-01-30 2007-02-05 Astellas Pharma Inc. Środek do leczenia dominującego zespołu drażliwego jelita grubego typu biegunkowego
EP1718148A2 (en) * 2004-02-03 2006-11-08 The Regents of the University of California Methods of treating irritable bowel syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
CA2557541C (en) * 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7317022B2 (en) * 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
MX2008010645A (es) * 2006-02-20 2008-10-14 Astellas Pharma Inc Derivado de amida o sal del mismo.
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
US8734867B2 (en) 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
SG10201503255SA (en) 2009-03-04 2015-06-29 Liveleaf Inc Method and material for site activated complexing of biologic molecules
EP2424550B1 (en) 2009-04-29 2017-06-07 Ganeden Biotech, Inc. Bacterial cell membrane formulation
JP5741433B2 (ja) * 2009-06-30 2015-07-01 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
WO2013057554A2 (en) * 2011-10-18 2013-04-25 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
AU2013312749B2 (en) * 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254584B1 (en) * 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
NZ226032A (en) * 1987-09-03 1991-12-23 Glaxo Group Ltd 2-(imidazolylmethyl)-pyrido or-azepino(4,3-b)indole-1(2h)-one derivatives; preparatory processes and pharmaceutical compositions
ATE108791T1 (de) * 1987-11-04 1994-08-15 Beecham Group Plc Neue 4-oxobenzotriazine und 4-oxochinazoline.
US5116984A (en) * 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
GB8820650D0 (en) 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (en) 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9020927D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) * 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
AU1161292A (en) 1991-01-09 1992-08-17 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
EA200000299A1 (ru) 2000-12-25
SV1998000122A (es) 1999-07-05
AU9629398A (en) 1999-04-27
NO20001776L (no) 2000-06-06
EE200000214A (et) 2001-06-15
UY25200A1 (es) 2001-01-31
US20010044450A1 (en) 2001-11-22
TNSN98179A1 (fr) 2005-03-15
GT199800157A (es) 2000-03-30
PL340337A1 (en) 2001-01-29
BR9812886A (pt) 2000-08-08
PE120299A1 (es) 1999-12-15
HN1998000155A (es) 1999-05-24
KR20010015707A (ko) 2001-02-26
AR017296A1 (es) 2001-09-05
IS5425A (is) 2000-03-31
AU750818B2 (en) 2002-07-25
JP2001518495A (ja) 2001-10-16
SK4862000A3 (en) 2001-01-18
US6284770B1 (en) 2001-09-04
MA26549A1 (fr) 2004-12-20
CN1281357A (zh) 2001-01-24
IL135398A0 (en) 2001-05-20
PA8461101A1 (es) 2000-05-24
ZA989061B (en) 2001-07-05
NO20001776D0 (no) 2000-04-06
GB9721139D0 (en) 1997-12-03
AP2000001785A0 (en) 2000-06-30
HUP0003750A2 (hu) 2001-10-28
EA003184B1 (ru) 2003-02-27
US20030036549A1 (en) 2003-02-20
CA2305751A1 (en) 1999-04-15
CO5011096A1 (es) 2001-02-28
HUP0003750A3 (en) 2003-02-28
US6593336B2 (en) 2003-07-15
YU20600A (sh) 2003-10-31
NZ503698A (en) 2002-10-25
EP1021174A2 (en) 2000-07-26
US6429209B2 (en) 2002-08-06
ID23874A (id) 2000-05-25
DZ2618A1 (fr) 2003-03-01
WO1999017755A3 (en) 1999-09-23
HRP20000198A2 (en) 2001-04-30
WO1999017755A2 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
AP2000001785A0 (en) Medicaments
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
TR199901417T2 (tr) Analjezik etkisi olan yeni bilesimler.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR199901172T2 (tr) Yeni ikame edilmis pirazol türevleri.
BR0215281A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores da função do receptor de hormÈnio nuclear
NO20003550D0 (no) Farmasøytiske sammensetninger og anvendelse herav
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
BR0113980A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
TR199802284T2 (tr) Dopamin D3 reseptörlerinin modülatörleri olarak tetrahidroizokuinolin türevleri.
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
NO20004419L (no) Ny anvendelse
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
YU13301A (sh) Muskarinski agonisti i antagonisti
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
TR199901385T2 (tr) Piperidin türevleri.
NO20005548L (no) Mykobakterieinhibitorer